Experimental design and optimization of raloxifene hydrochloride loaded nanotransfersomes for transdermal application
TL;DR: Ex vivo findings proved that a raloxifene hydrochloride-loaded transfersome formulation could be a superior alternative to oral delivery of the drug.
read more
Abstract: Raloxifene hydrochloride, a highly effective drug for the treatment of invasive breast cancer and osteoporosis in post-menopausal women, shows poor oral bioavailability of 2%. The aim of this study was to develop, statistically optimize, and characterize raloxifene hydrochloride-loaded transfersomes for transdermal delivery, in order to overcome the poor bioavailability issue with the drug. A response surface methodology experimental design was applied for the optimization of transfersomes, using Box-Behnken experimental design. Phospholipon® 90G, sodium deoxycholate, and sonication time, each at three levels, were selected as independent variables, while entrapment efficiency, vesicle size, and transdermal flux were identified as dependent variables. The formulation was characterized by surface morphology and shape, particle size, and zeta potential. Ex vivo transdermal flux was determined using a Hanson diffusion cell assembly, with rat skin as a barrier medium. Transfersomes from the optimized formulation were found to have spherical, unilamellar structures, with a homogeneous distribution and low polydispersity index (0.08). They had a particle size of 134±9 nM, with an entrapment efficiency of 91.00%±4.90%, and transdermal flux of 6.5±1.1 μg/cm2/hour. Raloxifene hydrochloride-loaded transfersomes proved significantly superior in terms of amount of drug permeated and deposited in the skin, with enhancement ratios of 6.25±1.50 and 9.25±2.40, respectively, when compared with drug-loaded conventional liposomes, and an ethanolic phosphate buffer saline. Differential scanning calorimetry study revealed a greater change in skin structure, compared with a control sample, during the ex vivo drug diffusion study. Further, confocal laser scanning microscopy proved an enhanced permeation of coumarin-6-loaded transfersomes, to a depth of approximately160 μM, as compared with rigid liposomes. These ex vivo findings proved that a raloxifene hydrochloride-loaded transfersome formulation could be a superior alternative to oral delivery of the drug.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Transferosomes: Unique vesicular carriers for effective transdermal delivery
TL;DR: This manuscript covers the current research advancements along with informative reports addressing the important issues and usefulness of prospective transferosomes with a better bioavailability profile.
Topical transdermal chemoprevention of breast cancer: where will nanomedical approaches deliver us?
TL;DR: The application of nanotechnology-based strategies for the delivery of well-established and new agents as well as drug repurposing using the topical transdermal route to improve the outcomes of preventive therapy for breast cancer are discussed.
11
A landscape of recent advances in lipid nanoparticles and their translational potential for the treatment of solid tumors
Radu A. Paun,Sarah Jurchuk,Maryam Tabrizian +2 more
- 09 Nov 2023
TL;DR: This review paper highlights recent developments in LNP drug delivery formulations and focuses on the treatment of solid tumors, while also discussing some of their current translational limitations and potential opportunities in the field.
11
Enhanced antioxidation via encapsulation of isooctyl p-methoxycinnamate with sodium deoxycholate-mediated liposome endocytosis
TL;DR: DOC-LS is a promising system for OMC dermal delivery without promoting skin irritation, which is quite advantageous for therapeutic purposes and corroborating the in vivo skin drug deposition results.
11
DOE-Assisted Formulation, Optimization, and Characterization of Tioconazole-Loaded Transferosomal Hydrogel for the Effective Treatment of Atopic Dermatitis: In Vitro and In Vivo Evaluation
Rohini Kharwade,Nematollahzadeh Ali,Purushottam S. Gangane,Kapil A. Pawar,Sachin More,Muzaffar Iqbal,A. Alasmari,Mohammed Kaleem +7 more
TL;DR: In this paper , a 32 factorial design was used to determine the therapeutic effects of transferosome carriers (TFs) for the treatment of atopic dermatitis (AD).
References
Cancer statistics, 2013
TL;DR: Overall cancer death rates have declined 20% from their peak in 1991 to 2009 and can be accelerated by applying existing cancer control knowledge across all segments of the population, with an emphasis on those groups in the lowest socioeconomic bracket and other underserved populations.
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures.
Olof Johnell,John A. Kanis +1 more
TL;DR: It is concluded that osteoporotic fractures are a significant cause of morbidity and mortality, particularly in the developed countries.
4.4K
•Journal Article
WHO Technical Report.
TL;DR: The Feather River Coordinated Resource Management Group (FR-CRM) has been restoring channel/ meadow/ floodplain systems in the Feather River watershed since 1985 and recognized the possibility of a significant change in carbon stocks in these restored meadows and valleys.
3.1K
The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial
Steven R. Cummings,Stephen Eckert,Kathryn A. Krueger,Deborah Grady,Trevor J. Powles,Jane A. Cauley,Larry Norton,Thomas Nickelsen,Nina H. Bjarnason,Monica Morrow,Marc E. Lippman,Dennis M. Black,Joan Ellen Glusman,Alberto Costa,V. Craig Jordan +14 more
TL;DR: The Multiple Outcomes of Raloxifene Evaluation (MORE) as discussed by the authors was a multicenter, randomized, double-blind trial, in which women taking raloxion hydrochloride or placebo were followed up for a median of 40 months at 180 clinical centers composed of community settings and medical practices in 25 countries, mainly in the United States and Europe.
1.8K
Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.
Pierre D. Delmas,Nina H. Bjarnason,Bruce H. Mitlak,Anne-Catherine Ravoux,Aarti Shah,William J. Huster,Draper Michael William,Claus Christiansen +7 more
TL;DR: Daily therapy with raloxifene increases bone mineral density, lowers serum concentrations of total and low-density lipoprotein cholesterol, and does not stimulate the endometrium.
1.6K